ストックスクリーナーアプリを入手
0.98
8.41%
-0.09
前日終値:
$1.07
開ける：
$1.08
24時間の取引高:
66,192
Relative Volume:
1.00
時価総額：
$3.83M
収益：
-
当期純損益:
$-9.87M
株価収益率:
-0.0248
EPS:
-39.4678
ネットキャッシュフロー:
$-8.76M
1週間 パフォーマンス:
-2.97%
1か月 パフォーマンス:
-5.77%
6か月 パフォーマンス:
-72.80%
1年 パフォーマンス:
-69.17%
1日の値動き範囲:
$0.98
$1.10
1週間の範囲:
$0.9515
$1.10
52週間の値動き範囲:
$0.875
$12.88
Revelation Biosciences Inc Stock (REVB) Company Profile
名前
Revelation Biosciences Inc
セクター
電話
650-800-3717
住所
4660 LAJOLLA VILLAGE DRIVE, SAN DIEGO
Compare REVB vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
REVB
Revelation Biosciences Inc
|
0.98 | 3.83M | 0 | -9.87M | -8.76M | -39.47 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Revelation Biosciences Inc (REVB) 最新ニュース
Revelation Biosciences Inc (REVBW) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Revelation Biosciences Inc (REVBW) Institutional Confidence - TradingKey
Revelation Biosciences Inc (REVBW) Valuation: PE, PB & Fair Value Analysis - TradingKey
Revelation Biosciences Inc (REVBW) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Revelation Biosciences Inc (REVB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Revelation Biosciences Inc (REVB) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Revelation Biosciences Inc (REVB) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Revelation Biosciences Inc (REVB) Valuation: PE, PB & Fair Value Analysis - TradingKey
Revelation Biosciences Inc (REVBW) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Revelation Biosciences Inc (REVBW) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Revelation Biosciences Inc - TradingKey
Revelation Biosciences Inc (REVBW) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Revelation Biosciences Inc (REVB) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Revelation Biosciences Inc (REVB) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Revelation Biosciences Inc (REVB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Revelation Biosciences Inc (REVB) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Revelation Biosciences, Inc. Financial Disclosures & SEC Filings - TradingView
REVB SEC FilingsRevelation Biosciences 10-K, 10-Q, 8-K Forms - Stock Titan
REVB Q1 2026 Earnings: EPS Misses Estimates by Wide Margin; No Revenue ReportedEPS Revision Trend - newsline.com
REVB Q1 2026 Earnings: Wider-than-Expected Loss Amid Pre-Revenue StageCFO Commentary Report - newsline.com
Revelation Biosciences forms advisory board for AKI trial - Investing.com
Revelation Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Newark Advocate
Revelation Biosciences expands AKI advisory board - Investing.com UK
Revel Releases Updated Corporate Presentation and Posts It to Website - TradingView
Revelation Biosciences (NASDAQ: REVB) furnishes new corporate presentation - Stock Titan
Revelation Biosciences expands AKI advisory board By Investing.com - Investing.com South Africa
Revelation Biosciences Expands Acute Kidney Injury Advisory Board - Rutland Herald
REVB Q1 2026 Earnings: Wider-Than-Expected Loss Highlights Pre-Revenue StageSubscription Growth Report - newsline.com
Revelation Biosciences (REVB) Shows Minimal Movement as Shares Trade Near Key SupportTime Weighted Price - newsline.com
REVB Q1 2026 Earnings: Significant EPS Miss as Cash Burn Continues Without RevenueReturn On Assets - thelegaladvocate.com
Revelation Biosciences (REVB) Inches Higher, Holding Above Key Support at $1.02Bear Pennant - The Legal Advocate
REVB Q1 2026 Earnings: Significant EPS Miss Amid Early-Stage DevelopmentEarnings Revision Downgrade - The Legal Advocate
REVB Q1 2026 Earnings: Staggering EPS Miss Highlights Ongoing Clinical Development CostsBook Value Growth - The Legal Advocate
Revelation Biosciences Inc. (REVB) Edges Lower, Maintains Support Near $1.01Exhaustion Gap - The Legal Advocate
REVB Q1 2026 Earnings: Wider-than-Expected Loss Highlights Pre-Revenue ChallengesEarnings Outlook Update - newsline.com
Revelation Biosciences (REVB) Faces Slight Decline as Key Support Levels Are TestedWave Extension - The Legal Advocate
Revelation Biosciences Q1 2026 Earnings: EPS Miss Highlights Ongoing Pre-Revenue StageStock Analysis Community - Newser
Revelation Biosciences Inc. (REVB) Q1 2026 Earnings: Wider-than-Expected Loss as Pre-Revenue Biotech Continues DevelopmentEarnings Yield Spread - Newser
Revelation Biosciences (REVB) Consolidates Near Key Support at $1.03Institutional Grade Picks - Newser
Why Revelation Biosciences Stock Jumped Today as Traders Eye Its Kidney-Drug Bet - Bez Kabli
Revelation Biosciences (REVB) Stock Forum and Discussion - Moomoo
Revelation Biosciences (REVB) Climbs +4.51% — Resistance at $1.07 in Focus 2026-05-18Community Risk Signals - Newser
Revelation Biosciences, Inc.Common Stock (NQ: REVB - The Chronicle-Journal
Armistice Capital reports 323,241 REVB shares (REVB) — 7.80% stake disclosed - Stock Titan
Revelation Biosciences announces pricing of $4M public offering - MSN
TradingKey - TradingKey
REVB Stock Price, Quote & Chart | REVELATION BIOSCIENCES INC (NASDAQ:REVB) - ChartMill
Revelation Biosciences Inc (REVB) 財務データ
収益
当期純利益
現金流量
EPS
0.74%
1.44%
大文字化:
|
ボリューム (24 時間):